The drug selectively inhibits the protein P2Y12, which is an Adenosine di Phosphate (ADP) receptor.
-
The drug is being sold under the trade name Brilinta in Brazil, Malaysia and... -
AstraZeneca developed the drug, which was approved for use in Canada in June... -
Blockage of a coronary artery which might lead to Acute Coronary Syndrome (ACS). -
The drug selectively inhibits the protein P2Y12, which is an Adenosine di...
